Thursday, Sept. 2

Room A

Time: 9:00-10:30

Round-table Discussion: Surgery-I

Chair: Valerie Rusch
(Thoracic Surgery Service, Department of Surgery Memorial Sloan-Kettering Cancer Center)

Harvey Pass
(Division of Thoracic Surgery and Thoracic Oncology, Department of Cardiothoracic Surgery, NYU Langone Medical Center and Cancer Center, USA)

RD02-1 A standardized technique of radical pleurectomy for mesothelioma that achieves a macroscopic complete resection, regardless of tumor bulk
Joseph Friedberg
(University of Pennsylvania, USA)

RD02-2 Surgical approach to MPM: The Brigham and Women’s Hospital experience
David Sugarbaker
(Division of Thoracic Surgery, Department of Surgery, Brigham and Women’s Hospital, USA)

RD02-3 Long-term outcome after extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: A 10-year single center experience
Masaki Anraku
(Division of Thoracic Surgery, Toronto General Hospital, University of Toronto, Canada)

RD02-4 Lung volume improvement in malignant pleural mesothelioma patients undergoing pleurectomy/decortication
William Sensakovic
(Committee on Medical Physics, The University of Chicago, USA)

RD02-5 Extrapleural pneumonectomy and pleurectomy/decortication in patients with malignant pleural mesothelioma: Is diaphragm resection really needed?
Enrico Ruffini
(Thoracic Surgery, University of Torino, Italy)

RD02-6 Should we stop operating on presumed stage III patients?
Hans Hoffmann
(Department of Surgery, Thoraxklinik, University of Heidelberg, Germany)

Round-table discussion
Time: 10:50-12:00

**General Session: Multimodality treatment**

**Chair:** David Sugarbaker  
(Division of Thoracic Surgery, Department of Surgery, Brigham and Women’s Hospital, USA)

**Takeshi Nagayasu**  
(Division of Surgical Oncology, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Japan)

**S17-1**  
**Keynote**  
Multimodality treatment paradigm for mesothelioma  
David Sugarbaker  
(Division of Thoracic Surgery, Department of Surgery, Brigham and Women’s Hospital, USA)

**S17-2**  
Tramodality therapy for malignant pleural mesothelioma: Radical pleurectomy followed by chemotherapy with cisplatin/permetrexed and radiotherapy  
Servet Bolukbas  
(Department of Thoracic Surgery, Dr.-Horst-Schmidt-Klinik, Germany)

**S17-3**  
Hyperthermic intrathoracic chemoperfusion (HITHOC) in combination with pleurectomy / decortication (P/D) for treatment of malignant pleural mesothelioma (MPM)  
K. Uwe Gruetzner  
(Munich Center for Thoracic Surgery, Asklepios Fachkliniken Muenchen-Gauting, Germany)

**S17-4**  
11 years single centre experience with induction chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma  
Isabelle Opitz  
(Division of Thoracic Surgery, University Hospital Zurich, Switzerland)

**S17-5**  
Feasibility study on multimodality therapy for MPM  
Seiki Hasegawa  
(Department of Thoracic Surgery, Hyogo College of Medicine, Japan)

Time: 14:00-14:40

**Workshop: Immunotherapy: bench to bedside-III**

**Chair:** Jeremy Steele  
(Department of Medical Oncology, St Bartholomew’s Hospital, UK)

**Yasuhiko Nishioka**  
(Department of Respiratory Medicine & Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan)

**WS08-1**  
A phase I clinical trial of two-dose intrapleural IFN-α gene transfer for malignant pleural mesothelioma  
Edmund Moon  
(Thoracic Oncology Research Group, University of Pennsylvania, USA)

**WS08-2**  
Systemic and tumour-associated T cells specific for 5T4 and other tumour antigens in mesothelioma and the design of a clinical trial with TroVax(R)  
Zsuzsanna Tabi  
(Cancer Immunology Research Group, Department of Oncology, School of Medicine, Cardiff University, UK)
WS08-3  Intratumoral immune stimulation combined with reduction of immunosuppressive factors prevents disease progression after debulking surgery in malignant pleural mesothelioma
Jarrod Predina
(University of Pennsylvania School of Medicine, USA)

Time: 14:40-16:00

Symposium: Carbon nanotubes and other possible causes of mesothelioma

Chair: Marie-Claude Jaurand
(INSERM, UMR 674, IUH Université Paris Descartes, France)
Seishiro Hirano
(Environmental Nanotoxicology Section, RCER, Natl. Inst. Environ. Studies, Japan)

SY01-1  Keynote
Responses of pulmonary cells to carbon nanotubes
Seishiro Hirano
(Environmental Nanotoxicology Section, RCER, Natl. Inst. Environ. Studies, Japan)

SY01-2  Diameter in nano-dimension of multi-walled carbon nanotubes and nanofibers is a critical factor in mesothelial injury and subsequent inflammation
Hirotaka Nagai
(Department of Pathology and Biological Responses, Nagoya University, Japan)

SY01-3  Nonasbestos fibers in the lung tissue of patients with mesothelioma give a hint for mesotheliomagenicity of nanofibers
Naomi Hisanaga
(Center for Campus Health and Environment, Aichi University of Education, Japan)

SY01-4  Rat ERC/mesothelin and early lesions of tumorigenic and non-tumorigenic fibrous materials including multi-wall carbon nanotube
Shuichi Adachi

Room B1

Time: 9:00-10:30

Workshop: Apoptosis and mesothelioma

Chair: Courtney Broaddus
(University of California, San Francisco Chief, Division of Pulmonary and Critical Care Medicine San Francisco General Hospital, USA)
Hirotoshi Akita
(Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Japan)

WS05-1  Keynote
Apoptosis and mesothelioma
Dean Fennell
(Center for Cancer Research and Cell Biology, The Queen’s University of Belfast, UK)

WS05-2  Keynote
The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance
Dario Barbone
(Lung Biology Center, SFGH, UCSF, USA)
WS05-3 Arsenic trioxide induces apoptosis through JNK and ERK in human mesothelioma cells
Ryoji Eguchi
(Department of Thoracic Oncology, Hyogo College of Medicine, Japan)

WS05-4 BRCA1 expression is required for efficacy of vinorelbine in malignant mesothelioma
Sara Busacca
(Center for Cancer Research and Cell Biology, The Queens University Belfast, UK)

WS05-5 Malignant mesothelioma resists against chemotherapies via mitophagy
Xiaobo Cao
(Department of Surgery, Scott & White Memorial Hospital and Clinic; the Texas A&M University System, Health Science Center, USA)

WS05-6 c-FLIP, a critical target for histone deacetylase inhibitors in malignant pleural mesothelioma
Jane Hurwitz
(Center for Cancer Research and Cell Biology, The Queen’s University Belfast, UK)

Time: 10:50-12:00

General Session: Clinical trials
Chair: Arnaud Scherpereel
(Pulmonary and Thoracic Oncology Department, Hospital of the University of Lille II, France)
Masahiko Higashiyama
(Department of Thoracic Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan)

S18-1 Valproic acid plus doxorubicin: effective therapy for progressing mesothelioma. A ELCWP phase II study
Arnaud Scherpereel
(Pulmonary and Thoracic Oncology Department, Hospital of the University of Lille II, France)

S18-2 A Phase II Trial of anti-TGFbeta Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma (MPM)
James Stevenson
(Thoracic Oncology Program, University of Pennsylvania School of Medicine, USA)

S18-3 Phase II study of pegylated arginine deiminase in patients with ASS1-negative malignant pleural mesothelioma
Peter Szlosarek
(Barts Cancer Research UK Center, UK)

S18-4 Retreatment with pemetrexed based chemotherapy (PBC) in patients with malignant pleural mesothelioma (MPM)
Giovanni Ceresoli
(Oncology, Humanitas Gavazzeni, Italy)

S18-5 Polysaccharide films: a drug delivery platform for loco-regional therapy of malignant pleural mesothelioma
Fabio Sonvico
(Pharmaceutical Department, University of Parma, Italy)
General Session: TNM staging for MPM

Chair: Valerie Rusch
(Thoracic Surgery Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, USA)
Hisao Asamura
(Division of Thoracic Surgery, National Cancer Center Hospital, Japan)

Introduction (Chairperson)

S20-1 Keynote
The International Association for the Study of Lung Cancer (IASLC) International Staging Committee (ISC): from retrospective to prospective registration of data
Ramon Rami-Porta
(Thoracic Surgery Service, Hospital Universitario Mutuade Terrassa, Spain)

S20-2
Applicability of proposed TNM modifications to biphasic mesothelioma
William Richards
(Division of Thoracic Surgery, Brigham and Women’s Hospital, Harvard Medical School, USA)

S20-3
Patterns of metastases to N2 lymph nodes from biphasic pleural malignant mesothelioma
Maria McIntire
(Department of Pathology, Brigham and Women’s Hospital, USA)

Time: 14:50-16:00

General Session: Surgery-II

Chair: Walter Weoler
(Division of Thoracic Surgery, University Hospital Zürich, Switzerland)
Hirohito Tada
(Department of Thoracic Surgery, Osaka City General Hospital, Japan)

S22-1 Keynote
A technique for accessing the fused pleural space for gene therapy or other intrapleural treatments for mesothelioma
Joseph Friedberg
(University of Pennsylvania, USA)

S22-2
Predictors of resectability in malignant pleural mesothelioma: Additive effects of volumetric analysis and preoperative pathophysiological variables. 5 year follow up and an update to IMIG 2008 report
Tamara Tilleman
(Division of Thoracic Surgery, Department of Surgery, Brigham and Womens Hospital, USA)

S22-3
The efficacy of argon beam ablation: Potential role in pleurectomy for mesothelioma
Andrea Wolf
(Division of Thoracic Surgery, Brigham and Women’s Hospital, USA)
S22-4  Extrapleural pneumonectomy for malignant pleural mesothelioma results correlated to selection criteria  

Cosimo Lequaglie  
(Thoracic Surgery, IRCCS Ospedale Oncologico Basilicata, Italy)

S22-5  Integrating immunotherapies with debulking surgery to target residual and metastatic mesothelioma  

Amanda Cleaver  
(National Centre for Asbestos Related Diseases, School of Medicine & Pharmacology, University of Western Australia, Australia)

Room B2  
Time: 9:00-10:30

General Session: Animal models  
Chair: Shinya Toyokuni  
(Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine, Japan)

Richard Lake  
(National Centre for Asbestos Related Diseases (NCARD) The University of Western Australia, Australia)

S16-1 Keynote  
Mechanisms of asbestos-induced carcinogenesis: Animal model studies  
Shinya Toyokuni  
(Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine, Japan)

S16-2 Keynote  
Animal models of malignant mesothelioma: An overview  
Richard Lake  
(National Centre for Asbestos Related Diseases (NCARD) The University of Western Australia, Australia)

S16-3  Role of protein kinase Cα and VEGF Receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of C. elegans model organism  
Rajani Kanteti  
(Section of Hematology/Oncology, Department of Medicine, University of Chicago, USA)

S16-4  Intrapleural application of polymeric films containing cisplatin and pemetrexed in a rat tumour model of malignant pleural mesothelioma  
Luca Ampollini  
(Thoracic Surgery, Department of Surgical Sciences, University Hospital of Parma, Italy)

S16-5  Mechanism of action of ADI-PEG20 in pleural malignant mesothelioma: in vitro and in vivo studies  
Barbara Delage  
(Institute of Cancer, Queen Mary University of London, UK)

S16-6  Staphylococcal enterotoxin-C, a pleurodesing agent, delays tumour growth in a murine model of malignant mesothelioma  
Sally Lansley  
(Lung Institute of Western Australia, Australia)
S16-7 MexTAg mice exposed to asbestos develop cancer that faithfully replicates key features of the pathogenesis of human mesothelioma
Cleo Robinson
(National Centre for Asbestos Related Diseases, University of Western Australia, Australia)

Time: 10:50-12:00

General Session: Prognostic factors

Chair: Jeremy Steele
(Department of Medical Oncology, St Bartholomew’s Hospital, UK)
Masao Nakata
(General Thoracic Surgery, Kawasaki Medical School, Japan)

S19-1 Keynote
Prognostic factors in malignant mesothelioma
Jacobus Burgers
(Department of Thoracic Oncology, The Netherlands Cancer Institute, The Netherlands)

S19-2 Identification of an estrogen-regulated gene associated with mesothelioma outcome
Melissa Coleman
(Division of Thoracic Surgery and the International Mesothelioma Program, Brigham and Women’s Hospital, and Harvard Medical School, USA)

S19-3 Circulating and tumor-infiltrating myeloid cells correlate with poor survival in non-epithelial malignant pleural mesothelioma
Bryan Burt
(Division of Thoracic Surgery, The Brigham & Women’s Hospital, USA)

S19-4 Validation of blood neutrophil-to-lymphocyte ratio as a prognostic factor in patients with malignant mesothelioma
Steven Kao
(Department of Medical Oncology, Sydney Cancer Centre, Australia)

S19-5 Extrapleural pneumonectomy for malignant pleural mesothelioma: Outcomes of treatment and prognostic factors
Tristan Yan
(Royal Prince Alfred Hospital, Sydney and The Baird Institute for Applied Heart and Lung Surgical Research, Australia)

Time: 14:00-16:00

General Session: Chemotherapy

Chair: Anna Nowak
(School of Medicine and Pharmacology, University of Western Australia, Australia)
Yuichi Takiguchi
(Department of Respirology, Graduate School of Medicine, Chiba University, Japan)

S21-1 In vitro chemoresistance to expanded drug panel in malignant pleural mesothelioma
Andrea Wolf
(Division of Thoracic Surgery, Brigham and Women’s Hospital, USA)
S21-2  Drug sensitivity and cytogenetic changes in primary malignant mesothelioma cells
Adam Szulkin
(Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet and University Hospital Stockholm, Sweden)

S21-3  Histoculture drug response assay for malignant mesothelioma of the pleura
Tatsuya Yoshimasu
(Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Japan)

S21-4  A clinical study of 34 malignant pleural mesothelioma patients treated with pemetrexed from Nagasaki Thoracic Oncology Group
Takaya Ikeda
(The Second Department of Internal Medicine, Nagasaki University Hospital, Japan)

S21-5  Optimized intrapleural cisplatin chemotherapy with a fibrin carrier after extrapleural pneumonectomy for malignant pleural mesothelioma: a pre-clinical study
Isabelle Opitz
(Division of Thoracic Surgery, University Hospital Zurich, Switzerland)

S21-6  Pemetrexed/carboplatin(AC) or pemetrexed/cisplatin(AP) as first line treatment of malignant pleural mesothelioma(MPM): tolerability and response rate in operable patients
Giulia Pasello
(Medical Oncology Department, Istituto Oncologico Veneto, IRCCS, Italy)

S21-7  2nd line oral vinorelbine following 1st line platinum + pemetrexed in inoperable malignant pleural mesothelioma (MPM)
Jens Sorensen
(Dept. Oncology, Finsen Centre, National University Hospital, Denmark)

S21-8  Chemotherapy practice in patients with malignant pleural mesothelioma in the UK; the ChIMP project
Michael Peake
(Mesothelioma UK, Glenfield Hospital, UK)

S21-9  Thymidylate synthase and excision repair cross-complementing group 1 as predictors of responsiveness in patients with malignant pleural mesothelioma treated with pemetrexed and carboplatin
Paolo Zucali
(Department of Oncology, Istituto Clinico Humanitas IRCCS, Rozzano, Italy)

S21-10 Personalized medicine in malignant mesothelioma: Can TS and ERCC1 predict response to chemotherapy?
Daniel Schwed
(Division of Pulmonary, Allergy and Critical Care Medicine, Hospital of the University of Pennsylvania, USA)
Enhanced expression of multidrug resistance (MDR) protein in malignant pleural mesothelioma (MPM) patients is possibly achieved via osteoponin, CD44 variants and p-AKT expression

Abeer Bahnassy
(Department of Pathology, National Cancer Institute, Cairo University, Egypt)

Annex Hall

Time: 9:00-10:30

Workshop: Immunotherapy: bench to bedside-I

Chair: Steven Albelda
(Thoracic Oncology Gene Therapy Program, University of Pennsylvania Medical Center, USA)
Toshihiro Nukiwa
(Department of Pulmonary Medicine, Tohoku University Graduate School of Medicine, Japan)

WS06-1 Chemotherapy alters cross-presentation of tumour antigen at the effector site
Alison McDonnell
(School of Medicine and Pharmacology, The University of Western Australia, Australia)

WS06-2 Novel internalizing human single chain antibodies targeting both common and treatment-resistant forms of mesothelioma
Scott Bidlingmaier
(UCSF Comprehensive Cancer Center, University of California at San Francisco, USA)

WS06-3 Anti-HM1.24 antibodies induce antibody-dependant cellular cytotoxicity against mesothelioma cells
Jun Huang
(Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan)

WS06-4 Tumor cell repopulation is inhibited by regulatory T cell depletion between cycles of chemotherapy in a murine mesothelioma model
Licun Wu
(Latner Thoracic Surgery Research Laboratories and Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Canada)

WS06-5 Gene therapy for malignant mesothelioma using urokinase-targeted oncolytic Sendai virus
Yosuke Morodomi
(Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Japan)

WS06-6 mRNA electroporated T-cells bearing mesothelin targeted chimeric antibody receptor have anti-tumor effect in a murine mesothelioma model
Edmund Moon
(Thoracic Oncology Research Group, University of Pennsylvania, USA)
WS06-7 Complete and sustained tumor regression of human malignant mesothelioma xenografts in athymic mice following local injection of midkine promoter-regulated oncolytic adenovirus
Shuji Kubo
(Laboratory of Host Defenses, Institute for Advanced Medical Sciences, Hyogo College of Medicine, Japan)

Time: 10:50-12:00

Workshop: Immunotherapy: bench to bedside-II

Chair: Daniel Sterman
(Section of International Pulmonology and Thoracic Oncology, Pulmonary, Allergy & Critical Care Division, University of Pennsylvania Medical Center, USA)
Ichiro Yoshino
(Department of Thoracic Surgery, Graduate School of Medicine, Chiba University, Japan)

WS07-1 Antibody-dependent cellular cytotoxicity mediated by cetuximab against mesothelioma cells
Hiroki Chikumi
(Division of Medical Oncology and Molecular Respiratory, Department of Multidisciplinary Internal Medicine, Tottori University, Japan)

WS07-2 Expression and regulation of B7-H3, a new member of the B7 family of immunoregulatory receptors, in human mesothelial and mesothelioma cells: immunotherapeutic implications
Luana Calabro
(Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Italy)

WS07-3 Oncolytic activity of measles virus against mesothelioma: potential role of the immune system
Nicolas Boisgerault
(INSERM U892, Cancer Research Center, Nantes, France)

WS07-4 Fiber-modified replication-competent adenoviruses powered by transcriptional regulatory region produced anti-tumor effects on mesothelioma and the differential cytotoxicity is linked with the replication and host cell mechanisms
Masatoshi Tagawa
(Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Japan)

WS07-5 Replication-competent E1B-55kDa deleted adenoviruses induce p53 up-regulation and apoptosis with mitosis arrest in mesothelioma cells
Yuji Tada
(Department of Respirology, Graduate School of Medicine, Chiba University, Japan)
Panel Discussion: Legal aspects

Chair: Paul Baas  
(Department of Thoracic Oncology, The Netherlands Cancer Institute, The Netherlands)
Toshiaki Higashi  
(University of Occupational and Environmental Health, Japan)

PD02-1 Keynote  
Mesothelioma at the intersection of law and medicine  
Steven Kazan  
(Kazan McClain Lyons Greenwood & Harley, USA)

PD02-2  
National tort claims by victims of asbestos textile industry in Japan  
Kuniko Kobayashi  
(Attorney at Law, Member of Osaka Lawyers Advocacy for the Victims of Pneumoconiosis & Asbestos disease, Japan)

PD02-3  
Brief history of Japanese asbestos litigations  
Naoki Ikeda  
(Kwansei Gakuin University Law School, Japan)

PD02-4  
Current situation on asbestos compensation in Japan  
Sugio Furuya  
(Ban Asbestos Network Japan (BANJAN), Japan)

PD02-5  
Summary of the situation in Europe  
Jacobus Burgers  
(Department of Thoracic Oncology, The Netherlands Cancer Institute, The Netherlands)

PD02-6  
Experience in Egypt and Africa  
Rabab Gaafar  
(Department of Medical Oncology, National Cancer Institute, Cairo University, Egypt)

PD02-7  
Moving beyond mesothelioma diagnosis - empowering patients to improve efficacy of treatment  
Linda Reinstein  
(Asbestos Disease Awareness Organization, USA)

Panel discussion